A 14-gene molecular assay may help identify early-stage non-squamous NSCLC patients who benefit from chemotherapy ...

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

DFS at 24 months improved from 79% with observation to 96% with the use of a 14-gene assay to guide decision making about ...

Tens of thousands of patients with lung and breast cancer are to benefit from a “revolutionary” blood test on the NHS across England which can speed up access to targeted therapy. The new ‘liquid ...

The screening—known as a liquid biopsy—is being rolled out to around 15,000 patients with suspected lung cancer, NHS England ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

People with lung cancer will be offered a new blood test designed to speed up access to targeted treatments and avoid ...

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can ...

Recent therapeutic advances have led to modest improvement in outcome for ... An example of a biomarker predictive of treatment response is chromosomal 1p and 19q tumor deletion among anaplastic ...